Original Article

Perceived Barriers to Contraceptive Access and Acceptance among Reproductive-Age Women Receiving Opioid Agonist Therapy in Northeast Tennessee

Authors: Edward Leinaar, MPH, Bill Brooks, DrPH, Leigh Johnson, MD, MPH, Arsham Alamian, PhD, MSc

Abstract

Objectives: Women with substance use disorders experience unique challenges to contraceptive obtainment and user-dependent method adherence, contributing to higher than average rates of unintended pregnancy. This study estimated the prevalence of barriers to contraception and their associations with contraceptive use and unwanted pregnancies among women receiving opioid agonist therapy (OAT) in northeast Tennessee.

Methods: A cross-sectional survey was piloted among female patients aged 18 to 55 years from 2 OAT clinics. Logistic regression was used to evaluate associations between contraceptive barriers and current contraceptive use and previous unwanted pregnancies among women receiving OAT.

Results: Of 91 participants, most experienced previous pregnancies (97.8%), with more than half reporting unwanted pregnancies (52.8%). Although 60% expressed a strong desire to avoid pregnancy, ambivalence toward becoming pregnant was common (30.0%). Most experienced ≥1 barriers to contraceptive use or obtainment (75.8%), the most prevalent being aversion to adverse effects (53.8%), healthcare provider stigmatization (30.7%), scheduled appointment compliance (30.3%), and prohibitive cost (25.0%). Experience of any contraceptive barrier (adjusted odds ratio [AOR] 8.64, 95% confidence interval [CI] 2.03–36.79) and access to a contraceptive provider (AOR 5.01, 95% CI 1.34–18.77) were positively associated with current use of prescribed contraceptives, whereas prohibitive cost was negatively associated (AOR 0.28, 95% CI 0.08–0.94).

Conclusions: Although most participants desired to avoid pregnancy, ambivalence or uncertainty of pregnancy intention was common. Most experienced barriers to contraception, which were more strongly associated with previous unwanted pregnancy than current contraceptive use. The provision of long-acting reversible contraceptives and contraceptive education at OAT clinics represents an opportunity to reduce the incidence of neonatal abstinence syndrome.
Posted in: Obstetrics and Gynecology27 Family Planning & Reproductive Health9

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Bonnie R, Ford M, Phillips J, eds. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington, DC:National Academies of Science, Engineering, and Medicine; 2017.
2. Wachman EM, Warden AH, Thomas Z, et al. Impact of psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity. Drug Alcohol Depend 2018;192:45-50.
3. Smith K, Lipari R. Women of childbearing age and opioids. The CBHSQ report. https://www.samhsa.gov/data/sites/default/files/report_2724/ShortReport-2724.html. Accessed March 7, 2020.
4. Parlier AB, Fagan B, Ramage M, et al. Prenatal care, pregnancy outcomes, and postpartum birth control plans among pregnant women with opiate addictions. South Med J 2014;107:676-683.
5. Am M, Mcdonald M, Md W. Neonatal Abstinence Syndrome Surveillance Annual Report 2017. Available at: https://www.tn.gov/content/dam/tn/health/documents/nas/NAS-Annual-Report-2017.pdf.
6. ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012;119:1070-1076.
7. Tennessee Department of Health. NAS Update Archive. https://www.tn.gov/health/nas/nas-update-archive.html. Accessed April 27, 2018.
8. Logan B, Brown M, Hayes M. Neonatal abstinence syndrome: treatment and pediatric outcomes. Clin Obstet 2013;56:186-192.
9. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998-2007.
10. Cornford CS, Close HJ, Bray R, et al. Contraceptive use and pregnancy outcomes among opioid drug-using women: a retrospective cohort study. PLoS One 2015;10:e0116231.
11. Black KI, Stephens C, Haber PS, et al. Unplanned pregnancy and contraceptive use in women attending drug treatment services. Aust NZ J Obstet Gynaecol 2012;52:146-150.
12. Collier KW, MacAfee LK, Kenny BM, et al. Does co-location of medication assisted treatment and prenatal care for women with opioid use disorder increase pregnancy planning, length of interpregnancy interval, and postpartum contraceptive uptake? J Subst Abuse Treat 2019;98:73-77.
13. Bornstein M, Gipson JD, Bleck R, et al. Perceptions of pregnancy and contraceptive use: an in-depth study of women in Los Angeles methadone clinics. Womens Health Issues 2019;29:176-181.
14. Hubacher D, Spector H, Monteith C, et al. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial. Am J Obstet Gynecol 2017;216:101-109.
15. Terplan M, Hand DJ, Hutchinson M, et al. Contraceptive use and method choice among women with opioid and other substance use disorders: a systematic review. Prev Med 2015;80:23-31.
16. Black KI, Day CA. Improving access to long-acting contraceptive methods and reducing unplanned pregnancy among women with substance use disorders. Subst Abuse 2016;10(suppl 1):27-33.
17. Poulton G, Parlier AB, Scott KR, et al. Contraceptive choices for reproductive age women at methadone clinics in western North Carolina. MAHEC Online J Res 2015;2:1-17.
18. Patrick SW, Schiff DM, , Committee on Substance Use and Prevention. A public health response to opioid use in pregnancy. Pediatrics 2017;139:e20164070.
19. Leinaar E, Johnson L, Yadav R, et al. Healthcare access, pregnancy intention, and contraceptive practices among reproductive-aged women receiving opioid agonist therapy in northeast Tennessee. South Med J 2019;112:382-386.
20. Harding C, Ritchie J. Contraceptive practice of women with opiate addiction in a rural centre. Aust J Rural Health 2003;11:2-6.
21. Kost K, Maddow-Zimet I, Kochhar S. Pregnancy desires and pregnancies at the state level: estimates for 2014. https://www.guttmacher.org/report/pregnancy-desires-and-pregnancies-state-level-estimates-2014. Published December 2018. Accessed March 7, 2020.
22. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-349.
23. Miller NS, Sheppard LM, Colenda CC, et al. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Acad Med 2001;76:410-418.